162. 類天疱瘡（後天性表皮水疱症を含む。） Pemphigoid Clinical trials / Disease details
臨床試験数 : 83 / 薬物数 : 128 - (DrugBank : 51) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05263505 (ClinicalTrials.gov) | February 21, 2022 | 16/2/2022 | Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid | Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid | Mucous Membrane Pemphigoid;Cicatrizing Conjunctivitis | Drug: Baricitinib 2 MG [Olumiant];Drug: Methotrexate;Drug: Azathioprine;Drug: Mycophenolate | Washington University School of Medicine | Eli Lilly and Company | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 2 | NCT02837965 (ClinicalTrials.gov) | April 2013 | 24/6/2016 | Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid | Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid | Bullous Pemphigoid | Drug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline) | CHU de Reims | NULL | Recruiting | 18 Years | N/A | Both | 150 | N/A | France |
| 3 | ChiCTR-TRC-12003538 | 2011-08-01 | 2012-12-27 | Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology, Chinese Academy of Medical Sciences | NULL | Recruiting | 18 | 0 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | China | |
| 4 | ChiCTR-TRC-12003593 | 2011-08-01 | 2012-12-30 | Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology; Chinese Academy of Medical Sciences | NULL | Completed | 18 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | China | ||
| 5 | NCT02313870 (ClinicalTrials.gov) | January 22, 2008 | 8/12/2014 | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid | Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid | Bullous Pemphigoid | Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone | University Hospital, Montpellier | NULL | Completed | 18 Years | N/A | All | 322 | Phase 3 | France |